GT Biopharma (GTBP) Competitors $0.71 +0.07 (+10.59%) Closing price 03:59 PM EasternExtended Trading$0.71 +0.00 (+0.40%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GTBP vs. PCSA, PHXM, DWTX, INAB, GOVX, APM, BFRI, MTNB, AEON, and EPIXShould you be buying GT Biopharma stock or one of its competitors? The main competitors of GT Biopharma include Heatwurx (PCSA), PHAXIAM Therapeutics (PHXM), Dogwood Therapeutics (DWTX), IN8bio (INAB), GeoVax Labs (GOVX), Aptorum Group (APM), Biofrontera (BFRI), Matinas Biopharma (MTNB), AEON Biopharma (AEON), and ESSA Pharma (EPIX). These companies are all part of the "pharmaceutical products" industry. GT Biopharma vs. Its Competitors Heatwurx PHAXIAM Therapeutics Dogwood Therapeutics IN8bio GeoVax Labs Aptorum Group Biofrontera Matinas Biopharma AEON Biopharma ESSA Pharma Heatwurx (NASDAQ:PCSA) and GT Biopharma (NASDAQ:GTBP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Do insiders and institutionals hold more shares of PCSA or GTBP? 91.9% of Heatwurx shares are held by institutional investors. Comparatively, 8.2% of GT Biopharma shares are held by institutional investors. 2.4% of Heatwurx shares are held by company insiders. Comparatively, 3.4% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Do analysts rate PCSA or GTBP? Heatwurx presently has a consensus target price of $1.00, indicating a potential upside of 258.42%. GT Biopharma has a consensus target price of $11.00, indicating a potential upside of 1,457.63%. Given GT Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe GT Biopharma is more favorable than Heatwurx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heatwurx 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 Is PCSA or GTBP more profitable? Heatwurx's return on equity of -342.36% beat GT Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets HeatwurxN/A -342.36% -243.48% GT Biopharma N/A -1,804.34%-200.12% Which has more risk & volatility, PCSA or GTBP? Heatwurx has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, GT Biopharma has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Does the media prefer PCSA or GTBP? In the previous week, Heatwurx and Heatwurx both had 2 articles in the media. Heatwurx's average media sentiment score of -0.50 equaled GT Biopharma'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heatwurx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Which has higher earnings and valuation, PCSA or GTBP? GT Biopharma is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHeatwurxN/AN/A-$11.85M-$2.32-0.12GT BiopharmaN/AN/A-$13.16M-$4.07-0.17 SummaryHeatwurx beats GT Biopharma on 6 of the 11 factors compared between the two stocks. Get GT Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for GTBP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GTBP vs. The Competition Export to ExcelMetricGT BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.27M$3.36B$6.16B$10.57BDividend YieldN/A2.28%5.50%4.66%P/E Ratio-0.1722.0285.5827.12Price / SalesN/A447.67608.62133.04Price / CashN/A46.3226.3031.10Price / Book-0.949.9612.876.67Net Income-$13.16M-$52.42M$3.30B$276.23M7 Day Performance21.76%5.95%4.80%3.31%1 Month Performance-24.87%11.59%8.11%10.76%1 Year Performance-65.04%25.01%75.85%33.58% GT Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GTBPGT Biopharma1.5813 of 5 stars$0.71+10.6%$11.00+1,457.6%-68.4%$2.27MN/A-0.178News CoveragePositive NewsShort Interest ↑High Trading VolumePCSAHeatwurx2.8814 of 5 stars$0.20-6.3%$1.00+401.0%-82.1%$10.72MN/A-0.0920Short Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049DWTXDogwood Therapeutics2.6202 of 5 stars$7.91+43.3%$10.00+26.4%N/A$10.55MN/A-0.425Gap DownHigh Trading VolumeINABIN8bio2.1538 of 5 stars$2.26-1.3%$180.00+7,864.6%-69.7%$10.40MN/A-0.2520High Trading VolumeGOVXGeoVax Labs2.2141 of 5 stars$0.63-2.6%$8.50+1,251.4%-72.0%$10.29M$3.95M-0.3110APMAptorum Group0.688 of 5 stars$1.82-1.6%N/A+34.7%$9.89M$430K0.0030Positive NewsShort Interest ↓Gap UpBFRIBiofrontera2.2825 of 5 stars$0.97+0.8%$2.75+184.1%+11.5%$9.73M$39.19M-0.4370Short Interest ↓Gap UpMTNBMatinas BiopharmaN/A$1.90flatN/AN/A$9.67MN/A-0.3930Gap UpAEONAEON Biopharma1.0004 of 5 stars$0.82-2.6%$360.00+43,802.4%-99.1%$9.55MN/A4.565EPIXESSA Pharma3.8714 of 5 stars$0.19-3.8%$2.00+934.1%-96.6%$9.51MN/A-0.3550Dividend AnnouncementGap Down Related Companies and Tools Related Companies Heatwurx Alternatives PHAXIAM Therapeutics Alternatives Dogwood Therapeutics Alternatives IN8bio Alternatives GeoVax Labs Alternatives Aptorum Group Alternatives Biofrontera Alternatives Matinas Biopharma Alternatives AEON Biopharma Alternatives ESSA Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GTBP) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredOctober 2025 Market Crash?Wall Street Legend Names #1 Stock [not NVDA] The greatest quantitative mind on Wall Street just revealed hi...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GT Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GT Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
